Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01179685
Other study ID # 2008-08-043
Secondary ID
Status Completed
Phase N/A
First received August 10, 2010
Last updated July 20, 2011
Start date January 2009
Est. completion date December 2010

Study information

Verified date July 2011
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Melanoma antigen (MAGE) gene is known to be expressed in tumor cells, testis and placenta. The purpose of this prospective study was to investigate the sensitivity, specificity and accuracy of pleural fluid MAGE gene expression, tumor marker and cytology in the diagnosis of malignant pleural effusion.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- unilateral pleural effusion on chest radiography

Exclusion Criteria:

- body temperature > 38.3ºC and peripheral blood leukocytosis (>12,000/µl)

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
pleural fluid tapping
Minimally invasive technique to detect malignant pleural effusion

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The purpose of this prospective study was to investigate the sensitivity, specificity and accuracy of pleural fluid MAGE gene expression, tumor marker and cytology in the diagnosis of malignant pleural effusion. 12months interval No